A project led by IBMB-CSIC tests molecules that stop the cytokine storm caused by SARS-CoV-2 Blog Post

A team of researchers led by Timothy Thomson’s group from the Barcelona Institute of Molecular Biology (IBMB-CSIC), based at the Barcelona Science Park, has developed a platform that allows to see in real-time if a drug inhibits the immune cellular response caused by SARS-CoV-2 infection. The project has the advantage that all the molecules being tested are previously known drugs and compounds that are used for other clinical indications. This would expedite the necessary procedures to propose, in due course, the use in patients with COVID-19.

 

Moirai Biodesign developes a diagnostic kit for the detection of sepsis in three hours Blog Post

Moirai Biodesign, a biotech start-up based in the Barcelona Science Park, has developed a prototype ‘kit’ based on biosensors that analyzes a blood sample and identifiesthe most important sepsis-causing pathogens and their associated antibiotic resistances, at the point of care and directly from the patient’s blood, in just three hours, a process that usually requires up to 5 days of analysis in the laboratory. The company has just received a €75,000 grant through the Startup Capital financing line from ACCIÓ to  to set about the activities derived from the execution of the initial business plan. Its objective is to market this device in hospitals, once the validation phase is completed.The kit will allow identification 

Scott Boyer joins Chemotargets as new CEO Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. With the new incorporation, the company, based in the Barcelona Science Park, consolidates its transition from a software business to an AI-driven biotech company.

 

Judit Cubedo, CEO of GlyCardial, finalist for the EU Prize for Women Innovators 2020 Blog Post

Judit Cubedo, co-founder and CEO of GlyCardial Diagnostics, is one of the twenty-one women selected as finalists for the EU Prize for Women Innovators 2020, an award given annually to the most talented and inspiring entrepreneurs in Europe. The company led by Judit, which is based in the Barcelona Science Park, is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia. The award winners will be announced at the European Research and Innovation Days taking place on 22-24 September 2020.

 

A global team involving ICUB-Tech researchers detects a type of unidentified astronomical object Blog Post

Researchers from the international collaborations LIGO and Virgo, in which the Institute of Cosmos Sciences of the UB (ICCUB) takes part under the coordination of Jordi Portell –co-director of the ICCUB Technology Unit, based in the Barcelona Science Park– have announced the discovery of an object of 2.6 solar masses, placing it firmly into so-called mass gap. That is an interval between the mass of the heaviest neutron star and the lightest blackhole, from which there were no observations yet.

 

IBEC researcher Pere Roca-Cusachs joins the European elite club in biology Blog Post

Pere Roca-Cusachs –group leader at the Institute for Bioengineering of Catalonia (IBEC) in the Barcelona Science Park and associate professor at the Faculty of Medicine of the University of Barcelona (UB)– has been chosen to join the European Molecular Biology Organization (EMBO), a prestigious network that brings together some of the most brilliant researchers in the world.

 

Chemotargets opens an investment round to enter a new phase of growth Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to expand its activity in the drug discovery sector as a biotechnology company. The company, based in the Barcelona Science Park, is opening an investment round to undertake the transformation of its business model, with tadvice and support of GENESIS Biomed, also located in the Park, and CREA Inversión.